FIGURE 4.

Therapeutic effect of Fc-μTP-L309C in acute Ab-mediated arthritis. (A) Protocol for evaluating therapeutic efficacy in CAbIA. (B) The clinical response to therapeutic administration of Fc-μTP-L309C (200 mg/kg) or IVIG (2000 mg/kg) i.p. at day 6 (arrow). PBS served as control. Kinetics of response (left) and mean clinical scores over days 7–14 (right) are shown. (C) CD45⁺ cells recovered from knee joints of mice at day 8 of disease. (D) Histopathology of arthritic joints. Representative H&E-stained sections of tarsal joints from arthritic mice at day 8. The joint of a naive nonarthritic mouse is also shown. Original magnification ×40. (E) Histological analysis of joints. Data show the mean (± SEM) histological scores of joints at days 8 and 14. All data are means ± SEM, pooled from two experiments. (F) Complement components C3 and C5a in arthritic mouse joint washes taken at day 8, determined by ELISA. Nonarthritic naive mouse joint washes were also included. Data show the complement component concentrations (means ± SEM), which have been normalized as a percentage of the PBS control. *p < 0.05, **p < 0.01, ***p < 0.001 compared with PBS control, (B and E) Kruskal–Wallis with Dunn test, (C and F) one-way ANOVA with Dunnett test.